Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability

This retrospective study analyzed survival outcomes of 174 metastatic GIST patients treated at a German referral center from 2008 to 2021. Median overall survival (OS) improved significantly compared to historical data, with OS of 7.1 years for imatinib, 2.9 years for sunitinib, and 1.9 years for regorafenib in respective treatment lines. Survival was influenced by metastatic site but not by prior perioperative imatinib or time to metastasis. The study offers valuable real-world survival data.